Novartis: More Pain on the Way? — Barrons.com
Can it get any worse for Novartis' U.S. stock?The Swiss company said Tuesday that del-desiran, part of a recent acquisition, reached the end of the line in a trial for a rare neuromuscular disease. Last week, another, pelacarsen, had failed to significantly reduce the risk of heart attacks and stro…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.